BioPharma Dive October 28, 2024
Novartis will pay the biotechnology company $150 million upfront to gain rights to an early-stage molecular glue degrader aimed at immune-mediated diseases.
Dive Brief:
- Novartis will pay $150 million to gain rights to “molecular glue degraders” being developed by biotechnology company Monte Rosa Therapeutics to target an immune signaling protein, known as VAV1, that has long been considered “undruggable.”
- The deal, announced by the companies Monday morning, could yield up to $2.1 billion in further payments by Novartis to Monte Rosa should the licensed research reach certain development, regulatory and sales milestones.
- Molecular glue degraders are small molecule drugs that join together a target protein with an enzyme responsible for flagging cellular detritus for disposal. In Monte Rosa’s case,...
Today's Sponsors
Today's Sponsor